Protein sequencing presents different challenges than nucleic acid sequencing, meaning that proteomics has yet to benefit as much as genomics from the next-generation sequencing revolution. However, ...

ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world’s first GMP-validated adventitious viral agent (AVA) ...

OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies today announced the expansion of its Compatible Products Programme (CPP), welcoming a new cohort of leading partners whose products now ...

OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a new collaboration with UK ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 3:30 PM EDTCompany ParticipantsNicholas Keher ...

Following on from the recent official launch of BGI’s new CycloneSEQ™ is the first independently reviewed benchmarking data. The CycloneSEQ™ platform delivers long-reads using novel nanopore ...

Detailed price information for Oxford Nanopore Tech Plc (ONTTF) from The Globe and Mail including charting and trades.

First-in-class solution consolidates multiple assays into a single test, enabling broader viral detection, faster time-to-result and more confident decision-making in regulated biopharmaceutical ...